Our group recently showed 50% neuronal cytotoxicity in nondiabetic cultured primary sensory neurons after 24-hour exposure to 0.25% ropivacaine, whereas clinically relevant concentrations of clonidine, buprenorphine, dexamethasone, and midazolam were nontoxic.7 As such, we feel that the investigation into the use of these perineural adjuvants should continue, especially within the framework of the ZDF model. The studies in this issue of Regional Anesthesia and Pain Medicine even suggest that dexamethasone is now a viable perineural adjuvant to study in DM because acute tissue hyperglycemia does not appear to influence neurotoxicity sequelae in primary sensory neurons in vitro and does not appear to influence crude long-term sensorimotor outcomes in vivo.
Buoyed by our report that clonidine, buprenorphine, and dexamethasone are nontoxic in cultured neurons,7 we created a clinical pathway at the Veterans Affairs Pittsburgh Medical Center involving the routine use of these perineural adjuvants with bupivacaine for single-injection regional anesthesia. The plan, which included the off-label perineural use of clonidine, buprenorphine, and dexamethasone, was presented to and approved by the hospitals Medical Executive Board before proceeding. Bupivacaine concentrations and analgesic adjuvant doses, as they differed for diabetic and nondiabetic in our clinical pathway, are presented in Tables 1 and 2. We analyzed quality improvement (QI) data for 101 lower-extremity joint replacement patients thus far (not intended to be interpreted as peer reviewed). Our mean nerve block durations of meaningful patient analgesia have been 41 hours (95% confidence interval, 3646 hours) for diabetic patients and 38 (3441 hours) for nondiabetic patients. If we include all regional anesthesia patients, there have been QI data entered for a total of 275 patients as of this writing, and there have been no peripheral nerve complications to date with respect to multimodal perineural analgesia.
Table 1
Image Tools
Table 2
Image Tools
There seems to be very promising reasons to continue to explore the coadministration of perineural adjuvants in combination with lower-concentration local anesthetics, even if local anesthetic toxicity risk with conventional concentrations is only minimally worsened by DM in current translational research. A recent review of peripheral nerve block complications suggests an incidence of 0.05%, or 1:20008; this does not appear to have changed over the past decade, despite the increasing use of ultrasound guidance and reduced local anesthetic volumes and concentrations.9 Others suggest that perineural complication rates for diabetic patients are 10 times greater than that for nondiabetic patients.10 Our specialtys diligence in the area of malignant hyperthermia has led to a remarkable small incidence, estimated to be 1:100,000.11 Can we not reach similar numbers with peripheral nerve block complications?
Clearly, continuing to allocate scarce research resources only to the study of local anesthetics in diabetic rat nerve block models appears to be somewhat wasteful, unless these studies actively adopt treatments that involve perineural analgesic adjuvants in an effort to significantly reduce (for surgical anesthesia) or eliminate (for perineural analgesia) local anesthetic use.
Ibinson, James W. MD, PhD; Mangione, Michael P. MD; Williams, Brian A. MD, MBA